French biotechnology company Brenus Pharma is set to present early clinical data from its experimental cancer treatment STC-1010 at the American Association for Cancer Research (AACR) Annual Meeting in San Diego this week, according to a company announcement.

The first-in-human trial data addresses a significant gap in cancer treatment: microsatellite-stable colorectal cancer (MSS CRC), a form of the disease that has proven largely resistant to existing immunotherapy approaches. While immunotherapy has transformed treatment for some cancer types, MSS colorectal cancer—which accounts for approximately 85% of all colorectal cancer cases—remains stubbornly unresponsive to these newer therapies.

A Different Approach to Immunotherapy

STC-1010 represents what Brenus Pharma calls a "next generation in vivo allogeneic immunotherapy" built on the company's Stimulated Ghost Cells (SGC) technology platform. Unlike traditional immunotherapies that work by blocking immune checkpoints or engineering a patient's own T-cells, this approach uses specially prepared donor cells to stimulate an immune response directly within the patient's body.

The poster presentation, scheduled for the conference running April 17-22, will provide what the company describes as a "translational overview" of how STC-1010 is administered in the metastatic MSS colorectal cancer setting. According to the announcement, early data show "favorable safety" and signs of "early immune engagement"—industry terminology suggesting the treatment is well-tolerated and appears to activate the immune system as intended.

Context and Caution

It's important to note that this represents very preliminary data from an early-stage trial. First-in-human studies are primarily designed to assess safety and determine appropriate dosing, not to prove effectiveness. The company has not disclosed the number of patients enrolled, specific safety metrics, or any data on tumor response rates.

The announcement also does not specify whether this is Phase 1 or Phase 1/2 trial data, nor does it indicate the trial's funding sources beyond Brenus Pharma itself. These details matter for interpreting the significance of the findings and understanding potential conflicts of interest.

Colorectal cancer remains the third most common cancer worldwide and the second leading cause of cancer death. The microsatellite-stable subtype has been particularly challenging because the tumors lack the high mutation burden that makes other cancers vulnerable to immune checkpoint inhibitors like pembrolizumab or nivolumab.

What Comes Next

The AACR presentation will be the first public disclosure of human data for STC-1010. Researchers and oncologists will be looking for several key indicators: the maximum tolerated dose, any dose-limiting toxicities, pharmacokinetic data showing how the treatment behaves in the body, and preliminary biomarker data suggesting immune activation.

Even positive early safety data represents only the first step in a lengthy development process. Most experimental cancer treatments that show promise in Phase 1 trials ultimately fail in later-stage studies when tested in larger patient populations or compared directly against standard treatments.

For patients with metastatic MSS colorectal cancer, current treatment options typically involve chemotherapy combinations, targeted therapies against specific mutations like KRAS or BRAF when present, or anti-EGFR antibodies in certain cases. An effective immunotherapy for this population would represent a meaningful advance, but proving that effectiveness will require considerably more data than what's being presented this week.

The full poster data will be available to conference attendees and may be published in summary form in the AACR conference proceedings. Whether Brenus Pharma will make detailed results publicly available beyond the conference presentation remains to be seen.